TSTickerStar
Company alerts/CMND
CMND company alerts

CMND updates worth following

TickerStar monitors official filings, investor releases, earnings, and call updates for CMND. Subscribe to CMND alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.

Official-source feed

Recent CMND alert previews

TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.

Company updateOfficial company source

Clearmind completes enrollment for Part C of CMND-100 Phase I/IIa trial

Clearmind Medicine announced that patient enrollment was completed for Part C of its CMND-100 Phase I/IIa clinical trial. Part C is a randomized, double-blind, placebo-controlled multiple-dose study evaluating safety, tolerability and pharmacokinetics at sites in the United States and Israel. The announcement did not include financial results or guidance.

Read source-backed brief
Debt offeringSEC filing

Clearmind Medicine to issue $2.0 million of convertible promissory notes to CLA Investors under amended SPAs

Clearmind Medicine Inc. announced on October 16, 2026 that it delivered a notice to the CLA Investors to issue and sell convertible promissory notes in an aggregate principal amount of $2,000,000 for an aggregate cash purchase price of $1,800,000 (90% of principal). The issuance is made under the securities purchase agreements dated September 17, 2025, as amended on April 30, 2026, which permit the issuance of convertible promissory notes in an aggregate principal amount of up to $10,000,000. The transaction is...

Read source-backed brief